Erik Lium, PhD, Named Vice President of Mount Sinai Innovation Partners
Dr. Lium previously held the post of Assistant Vice Chancellor for Innovation, Technology and Alliances at the University of California, San Francisco.
Erik Lium, PhD, a 16-year veteran with an extensive background in the academic, technology and medical sectors, has been named Vice President and Executive Director of Mount Sinai Innovation Partners, which facilitates the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships with industry. Dr. Lium previously held the post of Assistant Vice Chancellor for Innovation, Technology and Alliances at the University of California, San Francisco, where he led a team of scientists, attorneys, and business development professionals responsible for advancing UCSF’s research, instruction, and public service missions through the development of public-private research partnerships, management and licensing of technologies for commercialization, and entrepreneurship training and support.
During his nearly nine year tenure at UCSF, Dr. Lium was twice the recipient of grants from the National Science Foundation.
“Erik is a nationally recognized leader in innovation, public-private partnerships, technology transfer and commercialization, and we’re extremely proud to have an expert of his caliber join the team at Mount Sinai. I’m confident that under his leadership, MSIP’s role as a vital component of our institutional innovation agenda will expand,” said Scott L. Friedman, MD, Fishberg Professor of Medicine and Dean for Therapeutic Discovery at the Icahn School of Medicine at Mount Sinai.
Prior to his service at UCSF, Dr. Lium served in senior roles in information services companies focused on the pharmaceutical, biotechnology, and engineering sectors. In 2001, he co-founded LabVelocity, a software and information services company that provided life science research organizations with solutions to accelerate experimental design, as well as technology-based sales and marketing solutions for research tool vendors. In 2013, Dr. Lium testified before the U.S. House of Representatives’ Committee on Science, Space and Technology, Subcommittee on Research on the importance of technology transfer at universities, research institutes and laboratories, and approaches to foster innovation and commercialization.
“I’m thrilled to be joining Mount Sinai, a world-renowned institution committed to innovation and the development of partnerships with leading organizations in the pharmaceutical, medical device and information technology sectors for the specific purpose of improving health care delivery and increasing access to quality care,” said Dr. Lium. “Collaboration between academia and industry is critically important for the development and commercialization of new technologies and solutions that address unmet health care needs. The Mount Sinai Innovation Partners team excels at nurturing these types of relationships, and we look forward to increasingly collaborating with industry.”
Dr. Lium earned masters degrees in the arts and philosophy, and a PhD from the Integrated Program in Cellular, Molecular and Biophysical Studies at Columbia University; Dr. Lium served as a post-doctoral research scientist at Columbia and at the G.W. Hooper Foundation at UCSF, and graduated cum laude from Gonzaga University with a B.S. in Biology.
About Mount Sinai Innovation Partners (MSIP)
As part of the Icahn School of Medicine at Mount Sinai, MSIP facilitates the transfer of discovery from the laboratory to the marketplace, seamlessly linking a not-for-profit institution with for-profit commercial entities. MSIP manages efforts required to bring new inventions and technologies to market, providing a means to a healthier future. Our principal objective is to serve the community by transferring medical breakthroughs from Mount Sinai to the public while ensuring a consistent revenue stream to support the ongoing innovative efforts of Mount Sinai’s faculty and staff. Visit http://www.ip.mountsinai.org/ for more information.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.
Mount Sinai Health System Launches Elementa Labs, A Virtual Incubator Program
Jun 08, 2021 View All Press Releases